Table 5 Multivariable analysis for prognostic markers
From: Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
Marker | PFS HR (99% CI) | P -value | OS HR (99%CI) | P -value |
|---|---|---|---|---|
AFP (n=57) | ||||
⩽16 ng ml−1 | 1.00 | 0.49 | 1.00 | 0.58 |
>16 ng ml−1 | 1.30 (0.50–3.42) | 1.25 (0.45–3.52) | ||
HCG (n=45) | ||||
⩽4 mIU ml−1 | 1.00 | 0.17 | 1.00 | 0.15 |
>4 mIU ml−1 | 0.72 (0.21–2.45) | 2.35 (0.54–10.21) | ||
CA19.9 (n=55) | ||||
⩽40 | 1.00 | 0.06 | 1.00 | 0.60 |
>40 | 0.49 (0.18–1.35) | 0.81 (0.28–2.33) | ||
Chromogranin A (n=46) | ||||
⩽60 U l−1 | 1.00 | 0.017 | 1.00 | <0.001 |
>60 U l−1 | 2.77 (0.88–8.66) | 6.77 (1.26–36.50) | ||
Ki-67 % (n=72)* | ||||
<9 | 1.00 | 0.38 | 1.00 | 0.017 |
10–24 | 1.06 (0.43–2.59) | 1.18 (0.39–3.55) | ||
⩾25 | 1.51 (0.65–3.51) | 2.59 (0.98–6.83) | ||
Mitosis per 10 HPF (n=66)* | ||||
0–1 | 1.00 | 0.04 | 1.00 | 0.017 |
2–4 | 1.04 (0.43–2.51) | 1.29 (0.49–3.36) | ||
⩾5 | 2.29 (0.91–5.78) | 2.99 (1.07–8.36) | ||
